Alderson, P., Green, S. & Higgins, J. P. T. (eds) (2004) Cochrane Reviewers' Handbook 4.2.2. Chichester: John Wiley & Sons.
American Psychiatric Association (1998) Practice guideline for the treatment of patients with panic disorder. American Journal of Psychiatry, 155, 1–34.
Azhar, M. Z. (2000) Comparison of fluvoxamine alone, fluvoxamine and cognitive psychotherapy and psychotherapy alone in the treatment of panic disorder in Kelantan – implications for management by family doctors. Medical Journal of Malaysia, 55, 402–408.
Barlow, D. H., Gorman, J. M., Shear, M. K., et al (2000) Cognitive–behavioral therapy, imipramine, or their combination for panic disorder: a randomized controlled trial. JAMA, 283, 2529–2536.
Berger, P., Sachs, G., Amering, M., et al (2004) Personality disorder and social anxiety predict delayed response in drug and behavioral treatment of panic disorder. Journal of Affective Disorders, 80, 75–78.
de Beurs, E., van Balkom, A. J., Lange, A., et al (1995) Treatment of panic disorder with agoraphobia: comparison of fluvoxamine, placebo, and psychological panic management combined with exposure and of exposure in vivo alone. American Journal of Psychiatry, 152, 683–691.
Fahy, T. J., O'Rourke, D., Brophy, J., et al (1992) The Galway Study of Panic Disorder, I. Clomipramine and lofepramine in DSM–111–R panic disorder: a placebo-controlled trial. Journal of Affective Disorders, 25, 63–75.
Fava, G. A., Savron, G., Zielezny, M., et al (1997) Overcoming resistance to exposure in panic disorder with agoraphobia. Acta Psychiatrica Scandinavica, 95, 306–312.
Fava, G. A., Rafanelli, C., Grandi, S., et al (2001) Long-term outcome of panic disorder with agoraphobia treated by exposure. Psychological Medicine, 31, 891–898.
Foa, E. B., Franklin, M. E. & Moser, J. (2002) Context in the clinic: how well do cognitive–behavioral therapies and medications work in combination?
Biological Psychiatry, 52, 987–997.
Furukawa, T. A., Guyatt, G. H. & Griffith, L. E. (2002) Can we individualize the ‘number needed to treat’? An empirical study of summary effect measures in meta-analyses. International Journal of Epidemiology, 31, 72–76.
Gould, R. A., Otto, M. W. & Pollack, M. H. (1995) A meta-analysis of treatment outcome for panic disorder. Clinical Psychology Review, 15, 819–844.
Guy, W. (1976) ECDEU Assessment Manual for Psychopharmacology. Rockville, MD: US Department of Health and Human Services.
Higgins, J. P., Thompson, S. G., Deeks, J. J., et al (2003) Measuring inconsistency in meta-analyses. BMJ, 327, 557–560.
Hollon, S. D. & DeRubeis, R. J. (1981) Placebo–psychotherapy combinations: inappropriate representations of psychotherapy in drug–psychotherapy comparative trials. Psychological Bulletin, 90, 467–477.
Johnston, D. G., Troyer, I. E., Whitsett, S. F., et al (1995) Clomipramine treatment and behaviour therapy with agoraphobic women. Canadian Journal of Psychiatry, 40, 192–199.
Kampman, M., Keijsers, G. P., Hoogduin, C. A., et al (2002) A randomized, double-blind, placebo-controlled study of the effects of adjunctive paroxetine in panic disorder patients unsuccessfully treated with cognitive–behavioral therapy alone. Journal of Clinical Psychiatry, 63, 772–777.
Loerch, B., Graf-Morgenstern, M., Hautzinger, M., et al (1999) Randomised placebo-controlled trial of moclobemide, cognitive–behavioural therapy and their combination in panic disorder with agoraphobia. British Journal of Psychiatry, 174, 205–212.
Marks, I. M. & Mathews, A. M. (1979) Brief standard self-rating for phobic patients. Behavior Research and Therapy, 17, 263–267.
Marks, I. M., Gray, S., Cohen, D., et al (1983) Imipramine and brief therapists-aided exposure in agoraphobics having self-exposure homework. Archives of General Psychiatry, 40, 153–162.
Marshall, M., Lockwood, A., Bradley, C., et al (2000) Unpublished rating scales: a major source of bias in randomised controlled trials of treatments for schizophrenia. British Journal of Psychiatry, 176, 249–252.
Mattick, R. P., Andrews, G., Hadzi-Pavlovic, D., et al (1990) Treatment of panic and agoraphobia. An integrative review. Journal of Nervous and Mental Disease, 178, 567–576.
Mavissakalian, M. & Michelson, L. (1986) Agoraphobia: relative and combined effectiveness of therapist-assisted in vivo exposure and imipramine. Journal of Clinical Psychiatry, 47, 117–122.
Mavissakalian, M. R. & Perel, J. M. (2002) Duration of imipramine therapy and relapse in panic disorder with agoraphobia. Journal of Clinical Psychopharmacology, 22, 294–299.
Mavissakalian, M., Michelson, L. & Dealy, R. S. (1983) Pharmacological treatment of agoraphobia: imipramine versus imipramine with programmed practice. British Journal of Psychiatry, 143, 348–355.
Nathan, P. E. & Gorman, J. M. (2002) A Guide to Treatments That Work (2nd edn). New York: Oxford University Press.
Oehrberg, S., Christiansen, P. E., Behnke, K., et al (1995) Paroxetine in the treatment of panic disorder. A randomised, double-blind, placebo-controlled study. British Journal of Psychiatry, 167, 374–379.
Otto, M. W., Pollack, M. H. & Maki, K. M. (2000) Empirically supported treatments for panic disorder: costs, benefits and stepped care. Journal of Consulting and Clinical Psychology, 68, 556–563.
Schmidt, N. B., Koselka, M. & Woolaway-Bickel, K. (2001) Combined treatments for phobic anxiety disorders. In Combined Treatments for Mental Disorders (eds Sammons, M. T. & Schmidt, N. B.), pp. 81–110. Washington, DC: American Psychological Association.
Sharp, D. M., Power, K. G., Simpson, R. J., et al (1996) Fluvoxamine, placebo, and cognitive–behaviour therapy used alone and in combination in the treatment of panic disorder and agoraphobia. Journal of Anxiety Disorders, 10, 219–242.
Shear, M. K., Brown, T. A., Barlow, D. H., et al (1997) Multicenter collaborative panic disorder severity scale. American Journal of Psychiatry, 154, 1571–1575.
Sheehan, D. V., Ballenger, J. & Jacobsen, G. (1980) Treatment of endogenous anxiety with phobic, hysterical and hypochondriacal symptoms. Archives of General Psychiatry, 37, 51–59.
Simon, N. M., Safren, S. A., Otto, M. W., et al (2002) Longitudinal outcome with pharmacotherapy in a naturalistic study of panic disorder. Journal of Affective Disorders, 69, 201–208.
Song, F., Altman, D. G., Glenny, A. M., et al (2003) Validity of indirect comparison for estimating efficacy of competing interventions: empirical evidence from published meta-analyses. BMJ, 326, 472–476.
Spinhoven, P., Onstein, E. J., Klinkhamer, R. A., et al (1996) Panic management, trazodone and a combination of both in the treatment of panic disorder. Clinical Psychology and Psychotherapy, 3, 86–92.
Stein, M. B., Ron Norton, G., Walker, J. R., et al (2000) Do selective serotonin re-uptake inhibitors enhance the efficacy of very brief cognitive–behavioral therapy for panic disorder? A pilot study. Psychiatry Research, 94, 191–200.
Taylor, S. (2000) Understanding and Treating Panic Disorder. Chichester: John Wiley & Sons.
Telch, M. J., Agras, W. S., Taylor, C. B., et al (1985) Combined pharmacological and behavioral treatment for agoraphobia. Behavior Research and Therapy, 23, 325–335.
Thompson, S. G. & Sharp, S. J. (1999) Explaining heterogeneity in meta-analysis: acomparison of methods. Statistics in Medicine, 18, 2693–2708.
van Balkom, A. J., Bakker, A., Spinhoven, P., et al (1997) A meta-analysis of the treatment of panic disorder with or without agoraphobia: acomparison of psychopharmacological, cognitive–behavioral and combination treatments. Journal of Nervous and Mental Disease, 185, 510–516.
Wiborg, I. M. & Dahl, A. A. (1996) Does brief dynamic psychotherapy reduce the relapse rate of panic disorder?
Archives of General Psychiatry, 53, 689–694.
Zitrin, C. M., Klein, D. F. & Woerner, M. G. (1980) Treatment of agoraphobia with group exposure in vivo and imipramine. Archives of General Psychiatry, 37, 63–72.
Zitrin, C. M., Klein, D. F., Woerner, M. G., et al (1983) Treatment of phobias. I. Comparison of imipramine hydrochloride and placebo. Archives of General Psychiatry, 40, 125–138.